Bristol Myers Squibb has hit a snag in its Phase III trial investigating the company’s Opdivo and Yervoy combo in renal cell carcinoma, or RCC.
Researchers had been investigating Opdivo and Yervoy together as a potential treatment for patients who have undergone a full or partial removal of their kidney and who are at a higher risk of a relapse. But in a release Friday, part A of its Phase III study, dubbed CheckMate -914, “did not meet the primary endpoint of disease-free survival,” the company said.
Bristol Myers stated it will complete a full evaluation of the available data and work with investigators on the trial further.
“We are disappointed that the final analysis of CheckMate -914 Part A did not show this same benefit for the post-surgical treatment of patients with localized RCC. Nonetheless, we are dedicated to continuing research and advancing cancer care for all patients with…
Click here to view original post